204 related articles for article (PubMed ID: 22787150)
1. Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.
Ma J; Tang WK; Esser L; Pastan I; Xia D
J Biol Chem; 2012 Sep; 287(40):33123-31. PubMed ID: 22787150
[TBL] [Abstract][Full Text] [Related]
2. Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies.
Zhan J; Lin D; Watson N; Esser L; Tang WK; Zhang A; Liu X; Hassan R; Gleinich A; Shajahan A; Azadi P; Pastan I; Xia D
Cancer Res Commun; 2023 Feb; 3(2):175-191. PubMed ID: 36968141
[TBL] [Abstract][Full Text] [Related]
3. Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009.
Ma J; Tang WK; Esser L; Pastan I; Xia D
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Aug; 68(Pt 8):950-3. PubMed ID: 22869130
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Hassan R; Schweizer C; Lu KF; Schuler B; Remaley AT; Weil SC; Pastan I
Lung Cancer; 2010 Jun; 68(3):455-9. PubMed ID: 19744744
[TBL] [Abstract][Full Text] [Related]
5. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
Feng Y; Xiao X; Zhu Z; Streaker E; Ho M; Pastan I; Dimitrov DS
Mol Cancer Ther; 2009 May; 8(5):1113-8. PubMed ID: 19417159
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin targeted cancer immunotherapy.
Hassan R; Ho M
Eur J Cancer; 2008 Jan; 44(1):46-53. PubMed ID: 17945478
[TBL] [Abstract][Full Text] [Related]
7. Isolation of anti-mesothelin antibodies from a phage display library.
Chowdhury PS; Chang K; Pastan I
Mol Immunol; 1997 Jan; 34(1):9-20. PubMed ID: 9182872
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Hassan R; Cohen SJ; Phillips M; Pastan I; Sharon E; Kelly RJ; Schweizer C; Weil S; Laheru D
Clin Cancer Res; 2010 Dec; 16(24):6132-8. PubMed ID: 21037025
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
10. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
12. Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody.
Dangaj D; Abbott KL; Mookerjee A; Zhao A; Kirby PS; Sandaltzopoulos R; Powell DJ; Lamazière A; Siegel DL; Wolf C; Scholler N
PLoS One; 2011; 6(12):e28386. PubMed ID: 22163010
[TBL] [Abstract][Full Text] [Related]
13. An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope.
Li Y; Parry G; Chen L; Callahan JA; Shaw DE; Meehan EJ; Mazar AP; Huang M
J Mol Biol; 2007 Jan; 365(4):1117-29. PubMed ID: 17101149
[TBL] [Abstract][Full Text] [Related]
14. Mutual conformational adaptations in antigen and antibody upon complex formation between an Fab and HIV-1 capsid protein p24.
Monaco-Malbet S; Berthet-Colominas C; Novelli A; Battaï N; Piga N; Cheynet V; Mallet F; Cusack S
Structure; 2000 Oct; 8(10):1069-77. PubMed ID: 11080628
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the binding of an anti-cytochrome c antibody to its antigen: crystal structures of FabE8-cytochrome c complex to 1.8 A resolution and FabE8 to 2.26 A resolution.
Mylvaganam SE; Paterson Y; Getzoff ED
J Mol Biol; 1998 Aug; 281(2):301-22. PubMed ID: 9698550
[TBL] [Abstract][Full Text] [Related]
16. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
Rump A; Morikawa Y; Tanaka M; Minami S; Umesaki N; Takeuchi M; Miyajima A
J Biol Chem; 2004 Mar; 279(10):9190-8. PubMed ID: 14676194
[TBL] [Abstract][Full Text] [Related]
17. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Shin IS; Lee SM; Kim HS; Yao Z; Regino C; Sato N; Cheng KT; Hassan R; Campo MF; Albone EF; Choyke PL; Pastan I; Paik CH
Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258
[TBL] [Abstract][Full Text] [Related]
18. Two variable regions in carcinoembryonic antigen-related cell adhesion molecule1 N-terminal domains located in or next to monoclonal antibody and adhesion epitopes show evidence of recombination in rat but not in human.
Comegys MM; Lin SH; Rand D; Britt D; Flanagan D; Callanan H; Brilliant K; Hixson DC
J Biol Chem; 2004 Aug; 279(33):35063-78. PubMed ID: 15184366
[TBL] [Abstract][Full Text] [Related]
19. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers.
Brinkmann U; Webber K; Di Carlo A; Beers R; Chowdhury P; Chang K; Chaudhary V; Gallo M; Pastan I
Int J Cancer; 1997 May; 71(4):638-44. PubMed ID: 9178820
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond.
Almog O; Benhar I; Vasmatzis G; Tordova M; Lee B; Pastan I; Gilliland GL
Proteins; 1998 May; 31(2):128-38. PubMed ID: 9593187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
